PATTERSON, N.Y., Jan. 11, 2010 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that it initiated a Phase IIa clinical trial for A0001 in December and that the screening of patients is underway. The study is being conducted at The Children's Hospital of Philadelphia in patients with Friedreich's Ataxia (FA).
